Evaluation of Response of Dasatinib to Treat Mastocytosis
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single arm phase II non-randomized study of dasatinib in
which subjects with systemic mastocytosis (SM) will be treated with a continuous regimen of
dasatinib.
Upon completion of a treatment induction period, subjects will be treated with dasatinib at a
dose of 100 mg per os (OS) once daily (QD).